Abbott: We Do Deals
Executive Summary
Abbott's recent co-promotion with Boehringer Ingelheim is just one more in a series of events to suggest that its new top managers are bringing big changes to this tradition-bound company. In particular, Abbott no longer seems to be forcing deals to pass extraordinary economic hurdles (its finance department always used high cost estimates and low revenue projections to vet potential in-licensing candidates). The company's recognizing that with its anemic pipeline and more aggressive licensers, it's going to have to ante up to stay in the game.
You may also be interested in...
Vysis's Ship Comes In
Not too long ago, Vysis was just one of dozens of struggling genomic start-ups. Now, however, with its pending acquisition by Abbott Laboratories, it is a poster child for genomics success. Abbott is betting on the potential of Vysis's core position in fluorescent in situ hybridization (FISH) as a diagnostic tool, which allows users to evaluate disease based on changes at the chromosomal level. Abbott has been marketing Vysis's FISH test for the HER2 gene and since this summer.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.